RMD1202
Asset
Enables continuous subcutaneous production of a GLP-1 receptor agonist.
- Stage
- Preclinical
- Modality
- Gene therapy
- Target
- GLP1R
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Obesity
Preclinical, remedium-bio.com, 10 Oct 2026
Type 2 diabetes
Preclinical, remedium-bio.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.